Holen Sie sich die Stockscreener-App
11.82
1.91%
-0.23
Schlusskurs vom Vortag:
$12.05
Offen:
$11.97
24-Stunden-Volumen:
446.33K
Relative Volume:
0.32
Marktkapitalisierung:
$1.15B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-137.25M
KGV:
-6.254
EPS:
-1.89
Netto-Cashflow:
$-121.97M
1W Leistung:
-2.48%
1M Leistung:
+42.93%
6M Leistung:
+0.17%
1J Leistung:
+14.31%
1-Tages-Spanne:
$11.52
$12.10
1-Wochen-Bereich:
$11.33
$12.70
52-Wochen-Spanne:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Vergleichen Sie ORIC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
11.83 | 1.17B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.65 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.50 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
824.99 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.60 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.60 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 74% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oric Pharmaceuticals director Heyman sells shares worth $80,430 - Investing.com
ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside - Seeking Alpha
Short Interest in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Grows By 19.6% - MarketBeat
ORIC Pharmaceuticals (ORIC) Is Up 32.5% After J&J Lung Cancer Collaboration and Pipeline UpdateWhat's Changed - Sahm
ORIC Pharmaceuticals Stock Pre-Market (-6.1%) : Form 144 Filings Signal Intent to Sell - Trefis
First Week of March 20th Options Trading For Oric Pharmaceuticals (ORIC) - Nasdaq
Volume Summary: Is ORIC Pharmaceuticals Inc forming higher highs and higher lows2025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Is Roma Green Finance Limited gaining market shareJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration - Sahm
Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz - Yahoo Finance
H.C. Wainwright reiterates Buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones - MSN
Oric Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - marketscreener.com
ORIC: Advancing two late-stage oncology drugs with pivotal data and trials expected by 2027 - TradingView — Track All Markets
Wedbush Reaffirms Outperform Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Wedbush Reiterates Outperform Rating for ORIC at $20 | ORIC Stoc - GuruFocus
ORIC Pharmaceuticals reports progress on cancer drug candidates By Investing.com - Investing.com Nigeria
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ORIC Pharmaceuticals reports progress on cancer drug candidates - Investing.com
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones - Sahm
Oric Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.8% HigherShould You Buy? - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Biotech Gem with 148% Upside Potential - DirectorsTalk Interviews
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded by Piper Sandler to Strong-Buy Rating - MarketBeat
Why ORIC Pharmaceuticals Inc. stock attracts global investors2025 Price Targets & High Win Rate Trade Alerts - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy before product launchesQuarterly Trade Report & Capital Efficient Trading Techniques - Улправда
Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policiesEarnings Miss & Stock Timing and Entry Methods - Улправда
Options Flow: Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policies2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpWhat's Next? - MarketBeat
How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cutsVolatility Trading Techniques & Superior Capital Trading Plans - ulpravda.ru
Piper Sandler Initiates Coverage on ORIC with Overweight Rating and $22 PT | ORIC Stock News - GuruFocus
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating By Investing.com - Investing.com Canada
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating - Investing.com India
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - MSN
How to Invest in the U.S. Biotech Sector in 2026? Jefferies: Focus on These 6 Top Picks, 7 High-Potential Stocks, and 5 Key Acquisition Targets - Futubull
Squarepoint Ops LLC Invests $1.08 Million in Oric Pharmaceuticals, Inc. $ORIC - Defense World
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) surges as intriguing ESMO Asia data for Enozertinib prompts Wells Fargo to assign higher value - MSN
Will ORIC Pharmaceuticals Inc. stock benefit from green energy trendsWatch List & AI Optimized Trading Strategy Guides - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy on dipsDollar Strength & Growth-Oriented Investment Plans - DonanımHaber
Why retail investors favor ORIC Pharmaceuticals Inc. stockMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
How ORIC Pharmaceuticals Inc. stock reacts to job market dataExit Point & High Yield Stock Recommendations - DonanımHaber
Will ORIC Pharmaceuticals Inc. stock benefit from infrastructure spendingDividend Hike & Free Technical Confirmation Trade Alerts - DonanımHaber
Oric Pharmaceuticals (ORIC) Stock Analysis: Exploring a 157% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Heyman Richard A. | Director |
Jan 16 '26 |
Sale |
12.00 |
3,200 |
38,415 |
213,072 |
3.06%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):